Literature DB >> 15120653

Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2.

Jing Li1, Kathy N Tomkinson, Xiang-Yang Tan, Paul Wu, Grace Yan, Vikki Spaulding, Bijia Deng, Bethany Annis-Freeman, Kathleen Heveron, Richard Zollner, Gerard De Zutter, Jill F Wright, Tara K Crawford, Wei Liu, Kenneth A Jacobs, Neil M Wolfman, Vincent Ling, Debra D Pittman, Geertruida M Veldman, Lynette A Fouser.   

Abstract

Interleukin 22 (IL-22) is a cytokine induced during both innate and adaptive immune responses. It can effect an acute phase response, implicating a role for IL-22 in mechanisms of inflammation. IL-22 requires the presence of the IL-22 receptor (IL-22R) and IL-10 receptor 2 (IL-10R2) chains, two members of the class II cytokine receptor family (CRF2), to effect signal transduction within a cell. We studied the interaction between human IL-22 and the extracellular domains (ECD) of its receptor chains in an enzyme-linked immunoabsorbant assay (ELISA)-based format, using biotinylated IL-22 (bio-IL-22) and receptor-fusions containing the ECD of a receptor fused to the Fc of hIgG1 (IL-22R-Fc and IL-10R2-Fc). IL-22 has measurable affinity for IL-22R-Fc homodimer and undetectable affinity for IL-10R2. IL-22 has substantially greater affinity for IL-22R/IL-10R2-Fc heterodimers. Further analyses involving sequential additions of receptor homodimers and cytokine indicates that the IL-10R2(ECD) binds to a surface created by the interaction between IL-22 and the IL-22R(ECD), and thereby further stabilizes the association of IL-22 within this cytokine-receptor-Fc complex. Both a neutralizing rat monoclonal antibody, specific for human IL-22, and human IL-22BP-Fc, an Fc-fusion of the secreted IL-22 binding-protein and proposed natural antagonist for IL-22, bind to similar cytokine epitopes that may overlap the binding site for IL-22R(ECD). Another rat monoclonal antibody, specific for IL-22, binds to an epitope that may overlap a separate binding site for IL-10R2(ECD). We propose, based on this data, a temporal model for the development of a functional IL-22 cytokine-receptor complex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120653     DOI: 10.1016/j.intimp.2004.01.010

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

Review 1.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

Review 2.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

3.  Hypoxic modulation of hepatocyte responses to the cytokine interleukin-22.

Authors:  Scott A Budda; Krishna Bhattarai; Justine L Alexander; Lauren A Zenewicz
Journal:  Immunol Cell Biol       Date:  2016-10-31       Impact factor: 5.126

Review 4.  New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases.

Authors:  Jessica A Williams; Sharon Manley; Wen-Xing Ding
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

6.  Synthetic interleukin 22 (IL-22) signaling reveals biological activity of homodimeric IL-10 receptor 2 and functional cross-talk with the IL-6 receptor gp130.

Authors:  Sofie Mossner; Marcus Kuchner; Nastaran Fazel Modares; Birgit Knebel; Hadi Al-Hasani; Doreen M Floss; Jürgen Scheller
Journal:  J Biol Chem       Date:  2020-07-01       Impact factor: 5.157

Review 7.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

8.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Authors:  Hak-Ling Ma; Spencer Liang; Jing Li; Lee Napierata; Tom Brown; Stephen Benoit; Mayra Senices; Davinder Gill; Kyriaki Dunussi-Joannopoulos; Mary Collins; Cheryl Nickerson-Nutter; Lynette A Fouser; Deborah A Young
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

9.  Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains.

Authors:  Mario de Oliveira Neto; José Ribamar Ferreira; Didier Colau; Hannes Fischer; Alessandro S Nascimento; Aldo F Craievich; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Biophys J       Date:  2007-11-16       Impact factor: 4.033

10.  P27 deletion enhances hematopoiesis by paracrine action of IL22 secreted from bone marrow mesenchymal stem cells.

Authors:  Ruinan Lu; Qian Wang; Jianyong Li; Dengshun Miao
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.